Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.

A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

This is Allison’s personal multiple myeloma story, and others may be different. Allison is a paid spokesperson for GSK.

Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene ...

The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed ...

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

Bispecific antibodies have become component in the arsenal of treatments for hematologic malignancies; management of their side effects is crucial to their success.

Genmab (GMAB) stock was downgraded by Bernstein due to a looming patent cliff for Darzalex, a blood cancer drug marketed by the company with J&J (JNJ). Read more here.

A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient ...

In myeloma treatment, acute CRS is a common but treatable AE associated with CAR T-cell therapy and bispecific antibodies, ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...